Full Transcript Introduction to the Alzheimeru2019s Summit Interview 0:00 Hello and welcome to a very special interview for the Alzheimer's Summit. 0:03 I am your summit co-host, Doctor Christine Burke. 0:06 Over the last decade, I've helped many patients reverse their cognitive decline. 0:10 And in this summit, I am bringing you interviews with thought leaders 0:13 who can help you understand how to prevent and reverse cognitive decline 0:17 and Alzheimer's disease for yourself and your loved ones. 0:21 I cannot wait to introduce you to someone I have looked up to, 0:25 and whose work I have followed and admired for years. 0:28 One of our distinguished clinical luminaries in this field, 0:31 Doctor Richard Horowitz. 0:33 Doctor Horowitz is a board certified internist 0:36 and prior member of the HHS Tick Borne Disease Working Group 0:40 and New York State Department of Health Tick-borne working Group. 0:43 As medical director of the Hudson Valley Healing Arts Center. 0:46 He has treated over 30,000 chronic 0:49 Lyme patients with classical and integrative approaches. 0:53 He has created an effective model to address those with resistant 0:57 chronic illness called the M6 model and Dobson Combination Therapy, 1:02 discussed in his bestselling book How Can I Get Better? 1:05 And Action Plan for Treating Resistant Lyme and Chronic Disease, 1:09 and now expanded in his new book from Simon 1:12 and Schuster, out later this year, Ending Chronic Illness. 1:16 Doctor Horowitz's new book discusses how all 16 factors 1:19 underlying chronic Lyme disease and long Covid 1:23 are also found in Alzheimer's disease, and he recently submitted an article 1:27 to the Journal of Alzheimer's Disease Case Studies on reversing neuroinflammation 1:32 and detail levels in a patient with chronic Lyme disease 1:36 and post-treatment Lyme disease syndrome, using Dobson combination therapy. 1:40 Doctor Horowitz, I am so happy to have this opportunity to speak with you. 1:44 Welcome. Yes. 1:45 Thank you. I really appreciate you having me on the Alzheimer's Summit. 1:48 Very exciting. Very, very exciting. 1:51 So today we're exploring one of the more emerging areas 1:54 in Alzheimer's research how chronic infections 1:57 can contribute to neuroinflammation and cognitive decline. 2:00 And I'll bet this is a connection that most people, at least most 2:03 people outside of this summit, have never considered before. 2:07 As you've said to me before, it really is paradigm shifting. 2:10 I'd love for you to help us connect how a disease like Lyme disease 2:15 that most people 2:16 think of as a rash and a joint pain, something you treat and move on from. 2:20 Like how common is Lyme exposure and how is that linking 2:24 to infections as a contributor to Alzheimer's disease? 2:28 Yeah. No, it's it's an important question. 2:29 So you know, the reason people need to pay attention to Lyme disease, 2:33 which, by the way, is in epidemic proportion worldwide. 2:36 BMC Global Health A couple of years ago, they reported that 14.5% 2:41 of the global population, meaning one out of seven people 2:44 walking around on the planet right now has been exposed to Lyme. 2:48 So the problem there is the testing for this disease, which we can go through, 2:53 is not the most highly reliable in the world 2:55 because there are so many different strains of this bacteria. 2:58 So if you are diagnosed with a cognitive problem, as you get older 3:02 and they're calling it dementia, and in fact, they're even calling it 3:04 Alzheimer's dementia because they've done Pet scans, or 3:08 they've shown you that there's beta amyloid, whatever that they're doing. 3:11 Most people will not normally think about the fact 3:14 that Lyme disease can be one of the causes of Alzheimer's disease. 3:19 So, as you said earlier, people need to put together 3:23 that when you have beta amyloid. 3:24 And I think this is one of the things that escape people. 3:27 Bacteria can cause amyloid production in the brain. 3:30 Beta amyloid is not just showing up for no reason. 3:33 It's actually protective. 3:34 It's shows up whether you have viral 3:36 infections, bacterial infections, but it's actually protect your brain. 3:40 The problem is you create too much of it, just like then downstream with PTO, it
Lyme Disease and Alzheimeru2019s Risk 3:44 starts creating inflammation in the brain because of these biological markers. 3:49 Lyme is definitely one of the causes of Alzheimer's. 3:51 They've shown that the rates are 10 to 13 times higher. 3:55 If you have Spy Kids. 3:57 So they looked at Alzheimer's brain tissues and they found 4:00 not just spyer Keith's like Lyme, but identical to Spy Kids from the mouth. 4:04 That's why you've got to go to the dentist and take care of gingivitis 4:07 and poor Ramona's gingival and all those, you know, bugs that are there. 4:11 But Lyme definitely has been associated. 4:13 And what's exciting, 4:14 which I'm going to discuss with you today and this is brand new research. 4:18 I just submitted an article to the Journal of Alzheimer's Disease case Studies, 4:22 which was accepted with revisions, and I sent the revisions back yesterday. 4:26 We proved that we can reverse some of these 4:29 Alzheimer's markers that are now showing up in the blood, 4:32 like peto and beta amyloid, with a nine week oral antibiotic protocol. 4:37 This has never, ever been shown in the medical literature. 4:40 This is very exciting because if you happen to be one of these people 4:45 who is diagnosed with Alzheimer's and you have Lyme, this gives you hope. 4:49 Now again, we need a much larger study. 4:51 This is a case study that I submitted. Right. 4:54 So we can only go so far with, 4:55 you know, how far we were going to make recommendations. 4:58 But still, as I started testing my line patients in the last year, 5:02 I was finding detailed levels and beta amyloid ratios were off. 5:06 And I don't think the Lyme community knows this. 5:09 This is something that doctors need to look at, and now we at least have 5:12 one way we may be able to help reverse some of this neurocognitive decline. 5:17 Yeah, it is really exciting. 5:18 And corroborating the paper that you've just submitted 5:21 in our recent clinical trial, we also found a very high prevalence 5:26 of these types of chronic infections 5:28 and the Lyme and tick borne related infections in particular. 5:32 So you mentioned a moment ago that the testing is really variable. 5:36 And as people who do this work, we certainly know that. 5:38 But let's share a little bit with the audience 5:40 about some of the challenges in the testing 5:42 and how you recommend taking a stepwise approach. 5:46 Yeah. 5:46 So the most important thing that people need to know about testing 5:50 for Lyme disease is that it's a clinical diagnosis. 5:53 You do not make the diagnosis based on a test. 5:55 Now, if you were to go on the CDC site or speak to the health departments, 6:00 they want what's called a two tiered test. 6:02 They want a positive Elisa. 6:04 And if that Elyse is positive, they're going to do a Western blot. 6:08 The problem is that most of the Western blots are looking at one strain. 6:11 So when when they first originally did this, the B 31 strain, which is a lab 6:15 strain that goes back 34 years ago from the from the Dearborn conference, 6:19 we now have multiple strains of Borrelia the like cousins of the original strain. 6:24 And if you do a western blot 6:25 using one strain, you're obviously not going to pick up 6:28 the other eight major strains. 6:30 So we don't I don't ever do these days local Western blots, I use 6:34 what's called an immuno blot from my genex, 6:36 which was just approved by the FDA, by the way. 6:38 So the FDA now has approved a Lyme immuno blot. 6:41 There is an IgG. 6:43 So the way I do the clinical diagnosis is 6:46 we have a validated screening questionnaire 6:49 that we published back in 2017 and the International Journal of Medicine. 6:54 And I did this with Mariella Satara from the State University of New Paltz. 6:58 My good friend, Doctor Phyllis Freeman, PhD researcher. 7:01 And we looked at 1600 people 7:04 who had a chronic, fatiguing musculoskeletal neuropsychiatric illness. 7:07 Right. They were diagnosed with line. 7:09 But we also looked at normal people who said they didn't have it. 7:13 We were able to create a questionnaire and get it statistically validated. 7:17 And you can find the questionnaire on my website can get Better icon. 7:21 If you look under symptoms and questionnaire, 7:24 you'll find it there and you can download it. 7:26 And the way this questionnaire works is if you score over 63 on this questionnaire, 7:32 you have a very high probability of having Lyme. 7:35 If you score 45 to 62, you have a moderately high probability 7:39 between 25 and 42. 7:41 Mild probability below 25. 7:43 It's not likely that you suffer from Lyme disease. 7:46 But the key and this is really important with people with Lyme disease. 7:50 They have migratory pain. 7:53 There are only seven diseases in medicine that cause migratory pain. 7:57 So if you fill out this questionnaire and you have good and bad days 8:01 when the symptoms are coming and going and you don't know why, like there's 8:04 no reason and your joint pain, your muscle pain or your nerve pain, 8:09 tingling, numbness, burning, stabbing, vibration senses 8:12 they just move around your body for no good reason. 8:15 One day you've got it in your hands, and three days later it's in your shoulder. 8:18 And four days later it's in your legs. 8:20 It's moving around and you're thinking, I'm crazy, but you're not crazy. 8:24 That's what Lyme actually does. 8:26 So if you are tired and you have migratory pain or migratory neuropathy 8:31 with cognitive issues, then that migratory aspect tells you 8:35 that Lyme is going to likely be 8:37 one of the causes, because the other six causes of migratory pain 8:41 are not generally seen in clinical practice. 8:43 It's things like lupus, hepatitis, Crohn's and ulcerative colitis, 8:47 gynecologic righties, writer's disease, and acute rheumatic fever. 8:51 Now, yes, in 1 in 1000 shot you may have these diseases, 8:55 but generally when you go to a doctor with it, it's going to be Lyme. 9:00 So it's a clinical diagnosis. 9:02 And the labs are to confirm the clinical diagnosis. 9:05 So I like telling people to play a game called Lyme bingo. 9:09 And what this means is whether you do a Western blot 9:12 or my preference in immuno blot from my Gen-X,
Testing Challenges and Clinical Diagnosis of Lyme 9:15 if you have any one of the following bands that shows up on your immuno blot 9:20 bingo, you have been exposed to a Borrelia species. 9:24 Those bands are 23. 9:26 The outer surface protein C 31, the outer surface protein 9:31 A 34, the outer surface protein B 9:35 39, and the 83 slash 93 band. 9:38 You only need one band on an immuno blot with a high score on the Horowitz M6 9:44 questionnaire, which again you can find on my website, can't get better.com. 9:48 It tells you that you have been exposed to Borrelia. 9:51 Now understand in my world, if you have cognitive issues 9:54 and memory problems and you've been diagnosed with Alzheimer's 9:58 even by F-18 Pet scans, the problem is, is that 10:01 and this is what we just published in the medical literature, 10:04 we found that all 16 factors that we normally see in chronic Lyme 10:09 disease or post-treatment Lyme disease syndrome, meaning infections, 10:13 bacterial, viral, parasitic, fungal, environmental toxins, 10:18 microbiome issues with the gut, leaky gut and mast cell disorder. 10:22 Vitamin mineral deficiencies, sleep disorders, mitochondrial 10:26 dysfunction, Potts disorder, Nami, a hormonal dysregulation. 10:29 All of the things we found in Lyme have all been found 10:33 in Alzheimer's disease, which means we now opening up 10:37 like a whole nother avenue to hopefully get people better by saying hold on. 10:42 Toxins. 10:43 Heavy metals are found oftentimes with Lyme. 10:46 If you've not spoken to your doctor, if you have a Lyme diagnosis and diagnosed 10:50 with a demented illness, some of these patients that we've treated, 10:53 they're mold, they're metals, they're Lyme, they're Bartonella. 10:56 Their cognition gets better. 10:57 In fact, some combination therapy, which I published in this article, 11:02 it's number one effect is to improve cognition with memory concentration. 11:06 So it's it's really an exciting time. 11:08 But keep in mind the tests are unreliable. 11:11 And in my new book 11:11 that will be coming out later this year called Ending Chronic Illness, 11:15 I just got the book. 11:16 It just showed up from the publishers in Henley Chronic illness. 11:20 It's exciting. 11:21 In this book, I explain in great detail how to use these tests 11:24 because you can have an immunofluorescence assay and Elisa 11:29 AC6, Elisa a western blot and immuno blot. 11:32 There are a lot of indirect tests that you can use for Lyme and even direct 11:36 tests like PCR nano trap, where you find the bait in the urine. 11:41 Fish testing is one of my favorite, which is an RNA test. 11:43 We usually use it more for Bartonella and Berbizier, but the point being, 11:47 don't rely on one set of tests. 11:49 If you think you have Lyme, 11:51 you've got to make sure that you know it's a clinical diagnosis. 11:54 Look for those bands on the Western blotter, immuno blot 11:57 and also check for co-infections, because many times 12:00 the Busia Bartonella are associated with Lyme 12:03 and they will cause the same cognitive dysfunction 12:05 that you see in many of these Lyme patients. 12:08 Yeah, those are all 12:10 that is such a useful framework for people, because it really simplifies 12:14 something that can be quite complicated 12:17 in an application, and I appreciate that so much. 12:20 I'd add that, you know, I find often what I've been terming latent diagnosis 12:26 so people that don't necessarily meet the clinical diagnostic criteria 12:32 but have evidence of exposure on the immuno blot testing. 12:35 So we know that their immune system has been exposed to that bacteria, but 12:39 they've never had the classical symptoms or the symptoms like you've described 12:43 in the standardized questionnaire, which we use all the time in our practice. 12:47 So it's an interesting thing where I think 12:49 more people have had exposure than we realize, 12:52 because I don't know that everyone necessarily develops symptoms of disease. 12:56 What what is your thoughts on that? 12:58 So what's an excellent question? 13:00 I mean, I think the people who develop disease are usually number one, 13:04 the ones whose immune systems have been affected. 13:06 So first of all, Lyman, Bartonella, both affect the immune system. 13:10 We have many of our patients. 13:11 We published this years ago in the journal Health Care in 2018, 13:15 that about 20% of our patients have chronic variable immune deficiency. 13:19 They don't have the antibodies, immunoglobulins to fight infections, 13:23 or 85% of them 13:24 have subclass deficiencies, again impacting the way they fight infections. 13:29 But then a lot of these people have had long Covid and they get T-cell exhaustion. 13:33 So not only are there B-cells that make antibodies, but the T-cells 13:37 that fight viruses and cancer have also been affected by some of these viruses. 13:41 So many of these patients, their immune system is affected. 13:43 So if you get exposed to Lyme 13:46 and your immune system's not working correctly, you are going to get sicker. 13:49 The other ones who generally get it 13:51 are the ones that have had multiple tick bites, and the ones 13:54 with multiple co-infections, and especially the ones with more toxins, 13:57 because more toxins also suppress the immune system. 14:00 So if you're loaded with Clio toxins and aflatoxins and tricot thickens 14:04 and as we'll run on all these toxins we're finding in people, 14:08 it's similarly affects your immune system's ability to fight. 14:11 So the sickest people in our practice are usually the ones 14:15 that are loaded with toxins. 14:16 They don't just have Lyme, they have co-infections. 14:19 They have leaky gut. 14:20 They have the wrong types of bacteria in their gut 14:22 that don't make short chain fatty acids. 14:23 So they've got inflammation and that affects their blood brain barrier. 14:27 And they start seeing a lot of inflammation affecting their cognition. 14:30 So it's usually people that have multiple factors like multiple 14:35 overlapping causes of inflammation and downstream effects. 14:39 But you're right. 14:39 I mean, there are people 14:40 who have a healthy immune system could get bitten by a tick. 14:43 They might have very, very mild symptoms. 14:45 But you have to be careful because some of these people, you know, 14:48 they're a little tired or the little achy and they think, oh, it's the aches 14:52 and pains of daily living the way the IDSA sometimes describes it. 14:55 And I'm not saying that's not possible, but in my world, 15:00 these infections and toxins are getting into a large percentage of the population. 15:04 And and now knowing that really Bergdorf, 15:07 where I live, is associated with Alzheimer's disease 15:10 and raises your risk of it, according to what I've read in the literature 15:14 by tenfold and the statistics, because I just submitted this paper. 15:18 And I think people need to know this over 55 years old, 15:22 the risk of you may have discussed this 15:23 in the summit so far, but the risk of dementia is up to 42%. 15:28 I'm going to repeat that figure 4 to 2%. 15:31 Now that's ridiculous. 15:33 They know that the rates are doubling of Alzheimer's dementia. 15:36 But the problem in medicine and you know, this, Kristine, is we label illnesses 15:40 and we throw drugs at it. 15:41 So what you're going to label someone as a dementia case? 15:45 Here's your namenda right. 15:46 Here's your aricept instead of saying, hold on, 15:50 this dementia case may have all 16 factors underlying it. 15:54 I need to go look with a Lyme is there, but Busia, Bartonella 15:57 there are viruses reactivated like we see with long Covid. 16:01 You've got to go through the 16 point message model to see. 16:04 But the risk is enormous for people to have cognitive challenges 16:08 as they get older. 16:09 So I think 16:10 the model just needs to be shifted the way we're looking at it right now. 16:13 I totally agree with you. 16:14 And I think even even taking that a step back, like we've talked about before, 16:19 where we want to be looking for these things at a some level, 16:23 not necessarily as deep a level as we need to 16:25 when people are chronically ill, but we need to be looking at these factors 16:28 before the symptoms develop, because it's so much easier to correct 16:32 them before people have accumulated all 16 factors on the insides map. 16:38 And by the way, and this is where it gets tricky 16:40 if you ask most doctors when they go, if someone comes for a history and physical, 16:43 which you and I have done over the years, you know, go for your colonoscopy, 16:47 get your mammography, get your prostate exam, check your PSA, 16:50 there's bake, check your cholesterol, diabetes, hemoglobin A1, C. 16:53 But what is not being done because they don't know how to use 16:56 the markers is Peter 217 Peter 181. 17:00 Neural filament light and beta amyloid ratios 4240. 17:04 Now those four markers 17:05 I just mentioned, which are now available to request in LabCorp. 17:09 In this past year, before I started moving over to just consultation medicine, 17:14 I started checking my line patients, and I had 50 year old women 17:19 who said, yeah, you know, I've got a word finding problem here and there. 17:22 And the Peter 217 marker was elevated in the blood. 17:26 Now, that is one of the most significant markers
Latent Exposure, Immune Dysfunction, and Risk Factors 17:29 that you are going to go on and have a demented illness later on. 17:32 And I will tell you, and I'm guesstimating 17:34 because I have to go through the records. 17:36 But it's about 50% of the patients I was checking. 17:40 Their beta amyloid ratios were off. 17:43 I mean, just so you know, if you do these tests through your lab core, 17:46 it's kind of a first a an elevated P 217 or 181 is not what you want, 17:51 but a low beta amyloid 17:52 ratio is what it's a little reversed when you look at the lab tests. 17:55 It is. 17:56 But but just know we're finding these markers, these neuro markers. 18:01 Right. 18:01 That are implying you may go on to getting demented illness. 18:05 And probably half of our patients. 18:06 Now this article that I just submitted, 18:08 which should be published soon in the Journal of Alzheimer's 18:12 Disease Case Studies, what it showed is in this woman. 18:15 And by the way, I very few of these patients, most of my patients 18:18 have gone through some combination therapy, which we can discuss in a second. 18:22 It's a nine week oral generic antibiotic protocol I developed. 18:26 It took me ten years tweaking this to get it tweaked for Lyme, 18:29 where it's quite effective. 18:30 At least 50% of the people will go into long term remission 18:34 if they don't have the Busia Bartonella mold. 18:36 What we found in this woman and this is highly unusual. 18:39 My practice Eliza positive C6 Eliza 18:42 positive Western blot IgG am positive CDC, CDC, ICC, 18:48 Western blot positive, CDC positive, I am immuno blot and a rash. 18:53 This woman had every marker of post-treatment Lyme disease syndrome. 18:57 I could never have found a perfect case. 18:59 And she was 15 years with these symptoms after being treated with doxy sight clean. 19:04 And she also had evidence of Q fever. 19:06 Cox yellow Brunetti or licky of the Busia Bartonella. 19:09 So she had multiple infections. 19:11 15 years later she's got joint pain. 19:13 Rheumatoid factors are elevated 19:16 and she has peaked out to 17 levels high in her blood. 19:18 And I said to her, listen, your grandmother had Alzheimer's disease. 19:22 Let's check your EPO levels. 19:24 Turns out she was 33. 19:25 She did not have the genetic variant going on to its house. 19:28 And I said to her, listen, 19:30 I don't yet have evidence that that some combination therapy will lower these. 19:34 But there has been research published by IBA, Shopee and colleagues 19:38 that Lyme disease, Borrelia burgdorferi will be under biofilm. 19:43 It creates amyloid in p tau in the brain in people with Alzheimer's 19:47 and Parkinson's. 19:47 But these are brain tissues of autopsies. 19:50 Never in vivo, never a live person study. 19:53 We gave this woman the nine we Dobson protocol 19:56 and we tested her markers three months later. 19:59 The rheumatoid factors, which at one point were 33 I think over 20 20:03 is high, completely reverse back to normal with less joint pain. 20:07 Joint pain got better. 20:08 But what's amazing is the p tau 217 20:11 that was elevated at 0.33 reversed going down to 0.12 20:16 into the normal range after a nine week oral generic protocol. 20:21 This is never, ever been seen in the medical literature. 20:24 Now, this is exciting because if roughly and we don't know the numbers, 20:28 but if you read the literature, there are guesstimates that up 20:31 to 25% of the Alzheimer's cases are due to expire. 20:35 Kids. 20:35 Now that's a combination of Lyme disease, Borrelia, Bergdorf Rye, and dental call 20:39 as far as kids from the mouth. 20:41 But nevertheless, adoption protocol would still be treating this. 20:44 So we might have. 20:46 And again, it's one case study. 20:48 We need a multicenter, placebo controlled, randomized. 20:51 Right. 20:51 We know and I'm applying for these things so I can prove to the world 20:54 we have answers. 20:56 But this is exciting because this is the first time 20:58 it's ever been proven that we can lower down P2 17. 21:02 And what I didn't know until going through the literature, 21:05 when you lower P2 217 in the blood, 21:08 one of these markers that you may go on to Alzheimer's dementia. 21:12 It doesn't mean you have lower P2 levels in your brain. 21:15 It actually implies you have lower beta amyloid ratios. 21:17 And that's what we saw in this patient. 21:19 Her beta amyloid ratios, all they they were normal. 21:22 They improved after doing DAP shown meaning the load of beta amyloid went down 21:28 after we did the nine week home protocol. 21:30 Now again, we need to prove this in a larger population. 21:33 But this is very exciting for the 21:36 the doctors out there who say, gee, I've got an Alzheimer's case. 21:40 Did I check for Lyme? Did I check for Bartonella? 21:42 Did I check more? 21:43 This gives us a new paradigm of kind of look at these diseases and maybe 21:48 make headways so that we're not giving someone a life sentence. 21:52 Absolutely. 21:52 And that is a dramatic and remarkable result that you just told us about. 21:58 That's really amazing. Congratulations on. That. 22:00 Yeah. Thank you. 22:02 You know, it's been many years. 22:04 What I'm finding interesting, I've been in medicine now for 41, 42 years. 22:08 And what's interesting about this, 22:10 as a board certified internist who moved when I finished my Mount Sinai residency 22:14 in internal medicine and moved to the Hudson 22:16 Valley, New York, the highest Lyme endemic area in the world, 22:19 41 years later, I've seen 13,000 chronically aligned patients 22:23 who've come to me from all over the world. 22:25 But what's interesting is the model, in looking for answers 22:29 to this chronic Lyme population, what was completely unexpected 22:33 was that in looking for answers for them, creating the 16 point model, 22:37 I then was able to apply it and I published this on Long-covid 22:40 two years ago, that all 16 factors for chronic Lyme apply to long Covid. 22:46 All 16 factors apply now to Alzheimer's disease, right? 22:50 So in my new book, An Ending Chronic Illness and going through 22:54 all these diseases where we're now finding the 16 point M since model is there. 22:58 And by the way, Borrelia Bergdorf, right, shows up just like, by the way, 23:02 the Alzheimer research this past week they discussed chlamydia in pneumonia. 23:05 Right. 23:06 It's been talked about for a while that it's a potential the beauty 23:09 about some combination therapy is I am mixing 23:13 tetracyclines with the zits from mycin with rifampin with that zone. 23:17 I'm actually doing antibiotic protocols that would head chlamydia pneumonia. 23:21 So it's possible that this protocol 23:24 will be hitting multiple bacterial infections at the same time. 23:28 That may actually give us some results, right? 23:31 No matter whether it was mycoplasma pneumonia, whether it was chlamydia 23:33 pneumonia, because it's affecting a broad range of intracellular bacteria. 23:37 So, you know, it's kind of exciting that you do one thing in medicine, 23:41 which helps a group, and then you start expanding it out to other areas. 23:44 And that's why I'm so appreciative that I'm able to speak to you about this. 23:47 On the Alzheimer's Summit. 23:49 Because Alzheimer's disease, the numbers are doubling, 23:51 you know, in the next couple of decades. 23:53 And it's like, we've got to find better answers than what we have right now. 23:57 Absolutely, absolutely. 23:59 This is really exciting work. 24:01 Let's talk let's talk a little bit more. 24:02 So you've talked about how you studied this medication called DAP zone. 24:05 It has both antimicrobial and anti-inflammatory properties. 24:09 And we know that inflammation is a really central issue in Alzheimer's disease. 24:14 So talk talk a little bit more about the DAP zone how you're applying it. 24:17 What maybe some of the cautions are how how do we
Neuroinflammatory Biomarkers and Reversing Alzheimeru2019s Markers 24:21 how to make decisions about this. Yeah. 24:23 So what's really interesting about DAP zone and Alzheimer's disease. 24:26 Is there was a study published by doctor Lee in Korea, goes back a couple of years, 24:30 and he had over 3000 Korean patients with leprosy. 24:33 Now DAP so normally is a drug with rifampin. 24:36 And this is by the way 24:37 how I figured out how to use DAP shown for Lyme disease, rifampin and DAP zone. 24:40 It's used for leprosy for anywhere between 6 to 12 months, 24:44 depending on whether you have multidrug resistant leprosy or regular. 24:47 But this particular regimen was used in the leprosy population 24:51 and over 3000 people, and they followed them for 15 years. 24:54 What they found is that the leprosy patients 24:57 called Hansen's disease leprosy, who took rifampin and DAP. 25:00 Some part of the protocol I'm using, the levels of Alzheimer's disease 25:04 was like six times higher if they did not take the option 25:09 and much lower if they did. 25:10 So the theory behind this is that DAP 25:13 zone was acting as what they call an Nlrp3 inflammasome inhibitor. 25:17 So in other words, we've got these inflammatory pathways in our body. 25:20 And we know by the way, that every chronic disease you look at 25:24 from autism to ADHD to Alzheimer's, allergies, cancer, 25:28 it doesn't matter what you name it is due to chronic inflammation. 25:31 So with chronic inflammation, in this particular case, 25:34 what they suspected was happening with DAP zone 25:38 is that it was acting on an inflammatory pathway called the NLRB three. 25:41 Inflammasome also showed up with Covid at the time when when Covid was out there 25:46 in its worst form, and that it lowered down inflammation in the brain. 25:49 And that's how Daptone acted. 25:50 Now, it's possible that in my patient where we reversed 25:55 our 2017 and improved beta amyloid ratios, it's possible 25:59 Dobson was acting as an Nlrp3 inflammasome and had nothing to do with heading line. 26:03 We don't know this 26:04 until we do larger studies, but the interesting thing about it is 26:08 that's probably one of the ways that that zone is affecting the brain, 26:12 is it has excellent central nervous system penetration. 26:16 And I love the fact that DAPs have had already been published, 26:19 lowering Alzheimer's rates years before I ever published this case study. 26:23 In over 3000 people in Korea. 26:25 So, you know, taking this forward now about Appsumo, 26:29 we discovered about ten years ago that Lyme was a what's called 26:33 a biofilm, persistent bacteria like tuberculosis and leprosy. 26:37 This came out of John Hopkins University. 26:39 And about at the same time, 26:41 it was a shopee's group at the University of New Haven, Stanford. 26:44 They were kind of coming out at the same point, Kim Lewis lab 26:47 at northeastern, looking at the fact that why does line keep relapsing? 26:51 Because we used to give cell wall drugs like amoxicillin, Herceptin, 26:55 cystic drugs like flagella or plaque with all grapefruit seed extract, 26:58 intracellular drugs like zero. 27:00 And it would help, but the patients would relapse. 27:03 After we stopped the drugs, we thought it was 27:05 what were called the cystic forms or L forms cell wall deficient. 27:09 But in 2016, when Hopkins discovered this, I went to the medical literature 27:14 and he said, oh, you mean it's a persistent like tuberculosis, leprosy. 27:19 And because I had treated a lot of TB when I was doing 27:22 HIV medicine at Mount Sinai, this goes back into the 1980s. 27:26 At this point, 70s and 80s and residency. 27:29 I looked up the Iron Age rifampin periods 27:32 and amid all the TB drugs I was using, and I came across them. 27:35 And the thing about Dobson that struck me is, number one, it's anti-inflammatory. 27:40 Every symptom you get with Lyme, or even in Alzheimer's is due to inflammation. 27:44 Number two, great penetration into the brain. 27:46 I never have to use I.V. 27:47 drugs anymore for lime. 27:49 I just use these oral generic antibiotics. 27:52 We get autoimmune phenomenon in Lyme. 27:54 Dobson has autoimmune effects. 27:56 It basically lowers down autoimmune symptoms in the body. 28:00 It hits BBC. 28:01 It has somewhat of an anti-malarial effect. Right. 28:03 So it has all of these different effects in the body. 28:07 But you're correct. You're asking me about the side effects. 28:09 But it's not an easy drug to use. 28:11 Mainly because like I call this do no harm. 28:15 H is for hurts, A is for anemia, R is for rashes, and M is for meth. 28:20 Hemoglobin Amia. So what does this mean? 28:23 This means that when you start using dapt shown in this nine week protocol, you're 28:26 going to start killing off the bacteria and getting what are called heart 28:29 Simon reactions, which is an inflammatory reaction. 28:32 So your symptoms get worse temporarily. 28:34 Your fatigue, your joint pain, your neuropathy, your brain fog. 28:38 You know it all can get worse for a temporary period. 28:41 We have to detox you with things 28:42 like high dose glue to iron out, catalyzing the body to make it better. 28:46 But the worst side effects is the of harm is a and anemia and meth hemoglobin 28:51 Amia because the are for rashes even though it's a sulfa drug 28:55 people have told me oh I have a bactrim allergy. 28:58 I can't take sulfa. My thoughts is all trimethoprim. 29:00 They actually can take naps on 99 out of 100 times, 29:04 and I give them like an h1 h2 blocker, Zyrtec, Pepcid. 29:07 They're usually fine, but the anemia alone 29:10 interferes with folic acid metabolism in the body. 29:14 So I give massive doses of both. 29:16 Luca Vaughan and L methyl folate to help 29:19 stop the anemia from getting worse than it normally would be. 29:22 So when you take dapt stone, if you have a hemoglobin, 29:24 let's say a 14, when you start, you're going to be roughly ten. 29:28 When you get to the end of the protocol. 29:30 Rarely it will even drop six grams to eight. 29:33 That's usually the most I've ever seen. 29:35 It'll always come back to normal. 29:37 But if you're a woman who starts at 12 because you're iron deficient, 29:41 you want to make sure 29:42 you don't have any iron deficiency anemia, no B12 deficiency folic acid. 29:47 Before you start home. 29:48 So sometimes I have to start and stop the protocol because of the anemia. 29:52 If a woman is starting with a low hemoglobin. 29:54 But again this is important. 29:56 The labs always come back to normal. 29:58 The hemoglobin is when you don't carry oxygen well in your blood. 30:02 So we added in methylene blue which by the way has studies on Alzheimer's. 30:07 You may have discussed this in the summit. 30:08 They're using low dose methylene blue now for mitochondrial dysfunction 30:12 which is one of the hypotheses not just the amyloid hypothesis. 30:15 It's one of them as to why people get dementia. 30:18 We use methylene blue because it's very effective at reversing meth hemoglobin. 30:22 But methylene blue is also a persistent drug. 30:25 And it works with rifampin. 30:27 And centrum acts to help Bartonella. 30:29 So when I put together 30:30 this protocol, which took me about ten years of tweaking, it, 30:34 we have found the exact right, 30:36 you know, amount of methylene blue of daptone, etc. 30:39 to basically give you 30:41 a very good possibility of getting you into long term remission. 30:44 But the key with this is you have to be you have to have an enzyme called 30:48 G6, PD glucose six phosphate dehydrogenase. 30:51 If you don't have this enzyme, 30:53 and I've only found it missing in like 2 or 3 people in 40 years, you can get worse 30:58 anemia and worse mouth hemoglobin reactions from using the protocol. 31:02 So but most people will be able to take it. 31:04 But it's it's not an easy protocol. 31:06 I mean I tell people this is like cancer chemotherapy. 31:09 It it is not easy, but it is well worth it. 31:11 And my wife is now going on eight years in full clinical remission. 31:14 She was sick for 25 years. 31:17 She took 50 of Daptone felt great, relapsed after a year. 31:20 PCR positive for Lyme in her blood. It went all right. 31:23 She felt good with 50, but it wasn't enough to knock out the line. 31:26 I gave her 100 for six months. 31:28 She went, oh, I feel great. 31:29 We stopped it. 31:30 She relapsed. Now this is before I knew the correct dosage. 31:33 The correct dosage is 100mg of DAP on twice a day for four weeks. 31:37 When you finish double dose stop, someone with a four day high dose stops on pulse. 31:42 Just four days at 400. 31:44 If you don't have the Busia part, you don't have mold. 31:47 And this is what I did for this patient, by the way, that we just 31:50 published in the Journal of Alzheimer's Disease case reports. 31:53 That's what she did 31:54 was an eight and a half week protocol finishing up with high dose Tap zone.
Dapsone, Inflammation, and Treatment Cautions 31:58 And then three months later, her 32:00 her PTL levels were better, her beta amyloid ratios. 32:02 In other words, 32:03 she reversed her Alzheimer's markers using this 8 to 9 week oral protocol. 32:07 So all of these protocols, by the way, 32:10 they are published in my medical detective Substack. 32:13 I have a free Substack for people called Medical Detective. 32:16 If you look at the five Bartonella sub stacks, the entire protocol in detail, 32:21 your doctor can read this and also read the article 32:24 we published in the journal microorganisms back in 2023. 32:28 In 2024, 32:29 this entire protocol is published so that you don't need to come to me 32:33 for a consult. 32:34 I have given away all of the information that I've ever had 32:38 for the benefit of humanity and people out there. 32:40 So, you know, I do have a consult service, but I've tried to make it 32:43 so you don't need me. 32:44 Yes, I have consulted you before. 32:46 This is this is really I mean, it is an incredible paradigm shift in therapeutic, 32:52 not just in therapeutic intervention, but the timeline of treatment. 32:56 Like as I'm listening to you talking about this nine week protocol 33:00 and how quickly people can show improvement compared to at least 33:04 in our chronic Lyme patients in the past, the years of treatment that it often took 33:10 to try to get people to the other side of that disease, with the persistence 33:14 and the biofilm support for the, you know, bacteria to persist. 33:17 It's really it's really. Yeah. 33:19 And you know, I, 33:20 I submitted and we're going to be actually looking for other grants. 33:23 But and 33:24 I don't want to go into this in detail, but we did submitted our 34 NIH grant 33:27 because I'm absolutely convinced of what I've discovered. 33:30 And the reason we know it works. 33:32 We have a culture study in culture. 33:35 This was done through Iva Shopee's lab, where we showed that 33:38 adaption alone lowers the biofilm persist or forms a Borrelia. 33:41 But when you add, for example, rifampin to that zone, which they did 33:44 with leprosy, it lowers the biofilm load even more. 33:48 When you then add a tetracycline like minnow or doxy, it lowers it even more. 33:53 And then when you add your fourth drugs, it from acts lowers it even more. 33:56 So when we designed the protocol, we have culture studies showing that 34:00 a for drug regimen works better than three, works better than two. 34:03 You also will never get antibiotic resistance when you mix 34:06 these drugs together. 34:08 We use multiple biofilm agents in the protocol, but we also have an 34:12 animal study from Tufts University in mice where they showed that these animals, 34:16 these mice that had chronic Borrelia burgdorferi infections after doxy, 34:20 they gave them rifampin and DAP, shown in a cured them. 34:23 The mice, the mice, it was gone. 34:25 Now we don't like to use the word cure with Lyme disease. 34:28 But I will tell you I now have patients years and years in remission. 34:32 If I didn't cure them, I knocked out 99.9% of the bugs 34:36 to the point your immune system is handling it. 34:38 But I think for the people out there, again, going back to 34:41 because it's an Alzheimer's summit and neurocognitive problems, 34:45 keep in mind that every point on the 16 point M 34:48 since model right is now associated with Alzheimer's. 34:51 So you have to look for the bacterial infections like Borrelia 34:55 burgdorferi, chlamydia, pneumonia, even to fever, which this patient had. 34:59 Cox yellow has been associated with Alzheimer's. 35:02 Herpesvirus one, two, seven and eight 35:05 right have been associated Covid even sometimes will cause it. 35:08 Parasitic infections can cause it. 35:10 Fungal infections can cause it. 35:12 But mold toxins also cause neurocognitive problems, right? 35:15 As do heavy metals. 35:16 They've been associated even with neurocognitive decline. 35:19 So please don't accept the diagnosis of dementia 35:23 without going through all of these 16 points with your doctor and finding out 35:28 where is the inflammation coming from and then reversing it. 35:32 And I'm treating a patient now from Massachusetts, his F-18 35:35 pet scan showed that he had, you know, a high burden of amyloid. 35:39 The neurologist put him on lecanemab. 35:41 He wanted to start him on the count of Mab. 35:43 And I said to him, listen, I, I'm a little bit worried about shrinking 35:46 your brain and brain bleeds and side effects. 35:48 And it's never been shown that long term. 35:50 This is going to be what people need. 35:52 The neurologist never checked him for Lyme of Bartonella. 35:54 His Bartonella fish was positive. 35:56 His Lyme was positive. He has mold toxins. 35:59 So it's like you just started giving him a drug for Alzheimer's 36:03 without looking at the underlying inflammatory causes. 36:06 And now we're following his PTO and beta amyloid as we keep treating him 36:10 with pulsing for the Bartonella. 36:12 Now, again, I'm finishing up my practice. 36:14 I'm only doing consultation medicine going forward. 36:17 I mean, again, you can read about it. 36:18 It can get better.com for any people interested. 36:21 But please understand I'm not looking for work. 36:24 I'm very I'm very happy to play with my new golden retriever puppy 36:28 and my wife and play ping pong and have a life, but I will be on a book 36:31 tour later on for ending chronic illness, because this book, for me 36:36 is a summation of my life's work 36:39 of everything that I have discovered, and it will tell people 36:42 how to diagnose and treat not just the three BS Borrelia, 36:45 but Busia, Bartonella, but how this model applies 36:48 to all chronic diseases and many line patients, by the way, have ADHD, right? 36:52 They have been diagnosed with a demanding illness like Alzheimer's. 36:55 So it's a paradigm shift that I. 36:58 I hope that our new health care system at HHS, 37:01 I spoke, by the way, to the acting surgeon general, not the new one that's coming, 37:06 but I actually spoke to her two weeks ago about my findings. 37:10 So I'm trying to get in 37:12 at the high levels of HHS and also to get an NIH funded study 37:16 so I can prove to the world that we have answers 37:18 and maybe even let them look at this for chronic fatigue 37:22 syndrome, because in chronic fatigue syndrome, or 16, 37:25 since factors are associated in fibromyalgia or fibromyalgia. 37:30 Exactly. 37:31 So it's kind of like doctors are naming diseases 37:34 and throwing drugs at them instead of saying, well, hold on, 37:38 every major chronic disease has inflammation underlying it. 37:42 We now know there are 16 factors. 37:44 And by the way, there's a roughly 2000 scientific references backing up 37:47 this book. 37:48 They will all be on my website on Can't Get better.com, 37:51 because we couldn't even fit them in the book. 37:53 The books are ready 640 pages from Simon and Schuster. 37:56 They said we're I put this in the book. You better put. 37:58 So it's like your doctor if they need science. 38:01 And I think this is how people don't trust science these days. 38:04 Right? 38:04 I think people have become confused of what do I trust? 38:08 You need to have a doctor in the trenches for 40 years. 38:11 Who knows what works and what doesn't work, right? 38:13 You know this. 38:14 It's not enough to say it's been published in PubMed. 38:17 People have to come to you, Christine, and go, hey, I read this, 38:20 but does this, like, link up with what your experiences? 38:23 And I think that's how we're going to get people's 38:24 trust back is having doctors like you and I in the trenches who say, 38:28 you know, something gets published and it does work or it's published and, 38:31 you know, I have not found it to work so well. 38:33 I think that's where we need to go on this. 38:36 Yeah, I agree with you. 38:37 And I think, 38:38 you know, your point is so well taken that we've really adopted in medicine 38:42 this approach of just identification and treatment instead of recognition 38:48 and then searching for why, how did we get here? 38:51 How did this body become diseased? 38:54 We've kind of accepted the you know, the acute model of medicine, 38:58 like the strep throats and the acute pneumonia, 39:01 and that model where there's one thing that causes it and a treatment 39:05 that's going to reverse that. 39:06 And we've tried to apply that to all these chronic diseases 39:09 that have these multifactorial inputs, inputs like you have mapped out 39:14 for us in the episodes. 39:15 Yeah, yeah, yeah. 39:16 And I think again, and I think this is going to happen, 39:19 I think this is a major finding for me and even the Lyme community, 39:22 the Lyme docs out there, the people have been doing this for years. 39:25 They are not checking 39:26 these new Alzheimer's markers that you can get from quest and LabCorp. 39:30 I was shocked to see that the PTL 39:32 181, the PTL 217, the beta amyloid ratios 39:35 and neuro filament light, they were off and at least 50% of these patients. 39:39 Meaning it's not just enough to say, hey, 39:43 we're treating you with antibiotics or herbs or whatever we're doing. 39:46 We want to see these biomarkers, right? 39:49 We want to see these biomarkers go down to protect your brain going forward. 39:54 And so I'm hoping that this new article that I just submitted and and in my book 39:57 and in chronic illness, 39:58 it'll stimulate right, the scientific community to say, hold on. 40:03 We're we're all doing this a little bit differently. 40:05 But, you know, it's possible that shot therapy and I.V. 40:08 ozone and some of the things out there does that. 40:10 But does it we now have a bar to set, which we know the dapt zone 40:15 gets into the brain and looks like it may reverse these Alzheimer's biomarkers. 40:19 Do these other therapies do that. 40:21 So we're going to need much more studies to prove this. 40:24 But it's kind of an exciting time where we now may have answers 40:28 that we just didn't 40:28 have before for people with these chronic fatiguing neurocognitive illnesses. 40:32 Yeah, absolutely. 40:33 And I'll share with you in our precision primary care division in our practice. 40:38 We have been doing it up to 17 levels as a screen, 40:41 and we're probably I would need to go back and check my numbers as well. 40:44 But just off the top of my head, I would estimate we're probably at about 40:48 10% of those that are abnormal in people who are 50 and older. 40:54 So we can 40:55 we can already identify 40:56 before they have symptoms that these changes, the end result, 41:01 if you will, of the chronic inflammatory pathways are already starting to happen. 41:04 It gives us an opportunity to intervene. 41:07 And because of things like the M6 map and having, you know, and potentially this 41:11 type of treatment, right, we have ways that we can change this trajectory. 41:15 So it is worthwhile to find out. 41:17 It's absolutely worthwhile to be tested.
Broader Chronic Illness Model and Closing Remarks 41:20 Whereas before, you know, 41:21 why would you get tested when it was just going to have an inevitable decline? 41:25 That's what's changed. 41:26 Dementia is no longer inevitable, right? 41:29 And I think that's you made an extremely important point, 41:32 which is 41:32 you need to get tested for these markers, because in the past, 41:35 all you could do is here's some aricept, here's some Amanda, you didn't we didn't 41:38 really have in our toolbox all the things we have right now. 41:42 Now knowing that all 16 emesis factors are associated with cognitive decline, 41:46 you can work with your doctor 41:48 and look at these factors and find out and then see, well, what can we do. 41:51 Do we need to pull them all? Do we need to treat the bard? 41:53 Do we need to use dobsonian? 41:55 And I think even with Dobson, what's fascinating is here 41:58 you have a study from 3 or 4 years ago and over 3000 people showing that 42:02 the Alzheimer's rates with zone were like 5 to 6 times lower. 42:06 And yet no one took a generic drug that's been out for 50 plus 42:10 years and said, hey, why don't we try repurposing this medication? 42:15 The dose they use, by the way, in that study was 100 of that. 42:18 So I'm using 200 to 400, but 100. 42:21 My wife, even when she took a hundred years ago, 42:23 went, wow, my brain, my body, I mean, it works. 42:26 Well, what if that was enough for people where we gave them a little extra 42:30 folic acid? 42:31 You don't get a lot of meth 42:32 hemoglobin at 100 of daptone, and you can use glutathione to lower it. 42:36 What if that was enough for people? Right. 42:39 And it's never been looked at. 42:40 And I it's just it's amazing to me. 42:42 And I think part of 42:43 this is big pharma who's just looking for, you know, monoclonal antibodies. 42:47 And look it's all great to do this stuff. 42:49 But don't ignore things 42:50 that are right in front of you that can benefit the global population. 42:53 When we're in the middle of an epidemic of Alzheimer's, 42:55 just like we're in the middle of an epidemic of Lyme disease. 42:58 Oh my gosh, I know I'm just so grateful for this work that you're doing, 43:03 for your contributions to this field, for everything that you have gifted 43:07 to the scientific community from your website and your books. 43:11 It gets it's really incredible. 43:13 And I just feel so honored to know you. 43:15 I want to ask you if there's anything else 43:17 you want to add that we haven't covered yet, 43:19 because this has been an incredible discussion, incredibly informative, 43:24 and I'm just so grateful to you for your time and sharing all of this. 43:27 No, I mean, I think the most important point for people 43:30 is go get tested at this point with these new neuro inflammatory markers. 43:35 It was not something I learned as an internist, as I said. 43:38 I mean, it would like check your blood pressure, check your cholesterol, 43:42 diabetes, go for I would not have normally checked. 43:44 You're saying it's about 10% of your population and I'm guesstimating. 43:48 It's about 50%. 43:49 But again, with mine, I'm dealing with really severe neurocognitive issues. 43:52 And people keep in mind that it's not like you can check this 43:56 and say, there's nothing I can do. There are things you can do. 43:59 And I think that's the point is 44:00 we give people hope that we now know that there's a new approach. 44:04 You want to look at mold. 44:06 You want to look at every fact you're on the map. 44:09 When I looked at it, leaky gut mass health disorder, mitochondrial dysfunction, 44:14 Potts disorder, the infections, whether it was 44:16 viral, bacterial, we now have answers for these type of things. 44:20 They did a study and they prove recently that some of the antiviral drugs like Pam 44:24 site glitter did not work right for Alzheimer's. 44:26 They just published just a month or two ago. 44:29 But that's because and I don't think this is where the science needs to change. 44:33 We're not looking at this diseases from a multifactorial perspective. 44:36 It's kind of like you're naming the disease and then you're going, 44:40 it's a virus, or we're naming the disease and saying, here's the drug. 44:44 What we're not doing is saying that every one of these chronic, fatiguing 44:48 musculoskeletal neuropsychiatric illnesses has 16 underlying inflammatory factors. 44:54 And we need so this is the paradigm shift. 44:56 I just want to highlight this is what will be talked about in my new book. 45:00 You can look at it on the website. 45:03 And in chronic illness.com we just got the website up. 45:06 And please let people know about this, because I am so excited to share this 45:10 with the world and I really look forward at the Islets Conference. 45:12 You know, later this year talking to my colleagues, because 45:16 my colleagues need to be doing this. 45:17 They need to be checking these markers and checking to see now 45:21 with a new standard of care, a new bar that we're setting 45:24 is what you're doing, whether it's herbs, whether it's ozone. 45:27 So t daps on whatever it is we now need to start comparing for the benefit. 45:32 The Lyme community, 45:33 what we're doing in the same thing for the Alzheimer's community. 45:36 Right. This is a new way of approaching Alzheimer's. 45:38 Dementia is, you know, 42% of adults over 55 years old. 45:42 There's a chance you're going to get it. 45:44 I looked I was reading the literature when I submitted this article. 45:47 I was absolutely astonished. 45:49 I didn't know the rates were so bad. 45:51 So I'm glad you're doing the summit 45:53 and raising awareness of this, but know there is hope and there are some. 45:56 Now, a paradigm shift kind of on the horizon that I think 45:59 is really going to benefit people going forward. 46:01 I do too. 46:02 And you have an upcoming Healing Lyme summit as well, don't you? 46:06 Yes we do. 46:06 Doctor Maria Hinchey and I will be doing the upcoming Lyme summit, 46:10 and in fact, we will be talking specifically 46:11 about protecting the brain and neuroinflammation. 46:14 That's the focus of this year's summit because of this article that I submitted 46:17 to the Journal of Alzheimer's Case Studies, 46:19 which is brand new information that the Lyme community will now hear. 46:22 So, yeah, it's exciting new stuff because we're really making headway. 46:27 I mean, that's one of the things we'll be sharing in our summit, too. 46:29 Excellent, excellent. 46:30 And that's an inmate. Correct. 46:32 That will be airing in May. That's correct. Yeah. So stay tuned. 46:34 You can look at a Facebook doctor period Richard Horowitz will be posting it. 46:38 I'll probably even be discussing some of it on the Medical Detective subsection. 46:41 And so that's how to get more information on it. 46:44 Beautiful. 46:45 Oh my gosh. 46:46 Well, thank you again so much for your time, your generosity with your knowledge. 46:51 And to my viewers, if you have enjoyed this discussion today, 46:55 please join some of our other sessions where we continue 46:58 to dive into my passion, the root causes of cognitive decline. 47:02 See you soon!
Comments